| Citation: |
TONG Jinlong, TIAN Xiaoqiang, LI Ying, LU Shihui, WANG Lixue, WANG Haiyu. Theraputic Effect and Quality of Life Assessment in Patients with Neuropathic Pain Due to Bone Metastasis from Hepatocellular Carcinoma Treated with Radiotherapy and Pregabalin[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1214-1220. DOI: 10.3971/j.issn.1000-8578.2023.23.0645
|
To evaluate the short-term efficacy and quality of life of primary hepatocellular carcinoma patients after radiotherapy and pregabalin treatment for neuropathic pain with bone metastasis.
32 patients with primary hepatocellular carcinoma bone metastases were treated with radiotherapy combined with pregabalin treatment.Then, we prospectively studied the analgesic efficacy for neuropathic pain and quality of life, used the brief pain inventory and douleur neuropathique 4 questionnaire (DN4) to evaluate pain at baseline, one and two months after radiotherapy, assessed pain response using the international consensus endpoint definition of bone metastasis, and used European Organization for Research and Treatment of Cancer Research and Treatment Quality of Life Questionnaire (EORTC QLQ-C30) and bone metastasis module (QLQ-BM22) for quality of life assessment.
One and two months after radiotherapy, the average DN4 score of neuropathic pain decreased, and the objective pain relief rates were 62.8% and 68.6%, respectively.The physical, emotional, social, and role functional scores of EORTC QLQ-C30 functional scale significantly increased in the first month after radiotherapy.Symptom scale of pain (P=0.015), insomnia (P=0.035), and loss of appetite (P=0.022) improved, and fatigue was aggravated (P < 0.05).Two months after radiotherapy, the mean overall health score and all functional scale scores significantly increased than those at baseline.The scores of all symptom scales decreased, except fatigue, constipation, and financial difficulties (P < 0.05).In addition, pain responders showed significant improvement in emotional function (P=0.025) and physical function (P=0.029) in the functional scale and in pain (P=0.014) and fatigue (P=0.035) in the symptom scale.The QLQ-BM22 score showed that the painful sites (P=0.021) and pain characteristics (P=0.04) of the responders significantly improved compared with those of nonresponders two months after radiotherapy.
Radiotherapy combined with pregabalin can relieve neuropathic pain caused by bone metastasis from primary hepatocellular carcinoma and greatly improve the quality of life, particularly in pain responders.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Shkodra M, Brunelli C, Zecca E, et al. Neuropathic pain: clinical classification and assessment in patients with pain due to cancer[J]. Pain, 2021, 162(3): 866-874. doi: 10.1097/j.pain.0000000000002076
|
| [2] |
Zinboonyahgoon N, Luansritisakul C. Neuropathic pain feature in cancer-induced bone pain: does it matter? a prospective observational study[J]. Korean J Pain, 2023, 36(2): 253-267. doi: 10.3344/kjp.22392
|
| [3] |
Guo X, Xu Y, Wang X, et al. Advanced hepatocellular carcinoma with bone metastases: prevalence, associated factors, and survival estimation[J]. Med Sci Monit, 2019, 25: 1105-1112. doi: 10.12659/MSM.913470
|
| [4] |
罗清甜, 李朴朴, 李楠, 等. 血清及作为化疗所致神经病理性疼痛生物学标志物的研究[J]. 中国疼痛医学杂志, 2022, 28(9): 680-685. doi: 10.3969/j.issn.1006-9852.2022.09.006
Luo QT, Li PP, Li N, et al. Serum TLR4 and TLR9 as biomavkers for chemotherapy-induced neuropathic pain[J]. Zhongguo Teng Tong Yi Xue Za Zhi, 2022, 28(9): 680-685. doi: 10.3969/j.issn.1006-9852.2022.09.006
|
| [5] |
Mathieson S, Lin CC, Underwood M, et al. Pregabalin and gabapentin for pain[J]. BMJ, 2020, 369: m1315.
|
| [6] |
Edwards HL, Mulvey MR, Bennett MI. Cancer-Related Neuropathic Pain[J]. Cancers (Basel), 2019, 11(3): 373. doi: 10.3390/cancers11030373
|
| [7] |
万丽, 赵晴, 陈军, 等. 疼痛评估量表应用的中国专家共识(2020版)[J]. 中华疼痛学杂志, 2020, 16(3): 177-187. doi: 10.3760/cma.j.cn101379-20190915-00075
Wan L, Zhao Q, Cheng J, et al. Expert consensus on the application of pain evaluation questionnaires in China (2020)[J]. Zhonghua Teng Tong Xue Za Zhi, 2020, 16(3): 177-187. doi: 10.3760/cma.j.cn101379-20190915-00075
|
| [8] |
Chen Y, Wang Q, Zhou G, et al. Predictive model based on DCE-MRI and clinical features for the evaluation of pain response after stereotactic body radiotherapy in patients with spinal metastases[J]. Eur Radiol, 2023, 33(7): 4812-4821. doi: 10.1007/s00330-023-09437-y
|
| [9] |
Mendez LC, Raman S, Wan BA, et al. Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ-BM22: results of a Brazilian cohort[J]. Ann Palliat Med, 2017, 6(Suppl 1): S65-S70.
|
| [10] |
Amini A, Shinde A, Wong J. Palliative Radiation for Cancer Pain Management[J]. Cancer Treat Res, 2021, 182: 145-156.
|
| [11] |
Zheng XQ, Wu YH, Huang JF, et al. Neurophysiological mechanisms of cancer-induced bone pain[J]. J Adv Res, 2021, 35: 117-127.
|
| [12] |
Roos DE, Turner SL, O'Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05)[J]. Radiother Oncol, 2005, 75(1): 54-63. doi: 10.1016/j.radonc.2004.09.017
|
| [13] |
Rich SE, Chow R, Raman S, et al. Update of the systematic review of palliative radiation therapy fractionation for bone metastases[J]. Radiother Oncol, 2018, 126(3): 547-557. doi: 10.1016/j.radonc.2018.01.003
|
| [14] |
Sipilä R, Kemp H, Harno H, et al. Health-related quality of life and pain interference in two patient cohorts with neuropathic pain: breast cancer survivors and HIV patients[J]. Scand J Pain, 2021, 21(3): 512-521. doi: 10.1515/sjpain-2020-0177
|
| [15] |
Clemons M, Ong M, Stober C, et al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer[J]. Eur J Cancer, 2021, 142: 132-140. doi: 10.1016/j.ejca.2020.08.019
|
| [16] |
Cacicedo J, Ciria JP, Morillo V, et al. Pain response and quality of life assessment in patients with moderate/severe neuropathic pain due to bone metastasis undergoing treatment with palliative radiotherapy and tapentadol: A prospective multicentre pilot study[J]. J Med Imaging Radiat Oncol, 2020, 64(6): 859-865. doi: 10.1111/1754-9485.13088
|
| [17] |
Koufopoulou C, Mosa E, Charalampakis N, et al. Evaluation of quality of life outcomes following palliative radiotherapy in bone metastases: A literature review[J]. J Buon, 2019, 24(5): 1747-1760.
|
| [18] |
Cañón V, Gómez-Iturriaga A, Casquero F, et al. Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy[J]. Rep Pract Oncol Radiother, 2022, 27(3): 428-439.
|
| [1] | SUN Ying, LI Zhiming, KANG Ning, WANG Wenwen, WANG Aili, LI Tong. Clinical Study on Treatment of Bone Metastasis from Breast Cancer with Method of "Jian Pi Yi Qi Yang Xue Zhi Tong"[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 259-264. DOI: 10.3971/j.issn.1000-8578.2024.23.1126 |
| [2] | NI Ting, GAO Hongyu, ZHAO Dan, WANG Haicun. Effects of Nutritional Intervention on Nutritional Status and Quality of Life of Patients with Colorectal Cancer Treated with Postoperative Adjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(12): 1286-1290. DOI: 10.3971/j.issn.1000-8578.2022.22.0417 |
| [3] | CHEN Fuyi, WU Jieling, MA Lian. Long-term Rehabilitation Management of Childhood Acute Lymphoblastic Leukemia Survivors[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 893-898. DOI: 10.3971/j.issn.1000-8578.2022.22.0110 |
| [4] | XU Aibing, SHEN Qian, TIAN Siyuan, TAN Qinghe. Improvement of Sorafenib on Recent Quality of Life for Patients with Terminal-stage Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(12): 1187-1189. DOI: 10.3971/j.issn.1000-8578.2013.12.018 |
| [5] | Gu Mofa, He Weiling, Chen Xinlin, Xiao Weiwei, Su Yong, He Zhenyu, Li Jianjun, Zhang Huaman. Measurement Psychology Assessment for Quality of Life Evaluated by QLQ-C30 in Patients with Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2012, 39(09): 1079-1082. DOI: 10.3971/j.issn.1000-8578.2012.09.009 |
| [6] | Luo Jie, Wu Fengying, Zheng Di. Effect of Informed Status on Quality of Life in Lung Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2012, 39(07): 855-859. DOI: 10.3971/j.issn.1000-8578.2012.07.023 |
| [7] | LI Zhong-ping, HE Yu-min, SHEN Hong-yi, XU Hui. Research on QOL of Cancer Survivor in Tongzhou County of Jiangsu Province[J]. Cancer Research on Prevention and Treatment, 2011, 38(06): 701-705. DOI: 10.3971/j.issn.1000-8578.2011.06.026 |
| [8] | LI Wei, PIAO Hong-ying, QU Di, KONG Ling-juan, ZHANG Bao-ning, XUAN Li-xue, LUAN Jie, MU Da-li, XIN Min-qiang, MU Lan-hua. Assessment of Quality-of-life Influence of Immediate or Delayed Autologous Breast Reconstructions[J]. Cancer Research on Prevention and Treatment, 2011, 38(05): 535-538. DOI: 10.3971/j.issn.1000-8578.2011.05.014 |
| [9] | XU Chao-jiu, DING Chun-zhi, ZHOU Guan-zhen, FU La-lian, XIANG Zhi-bi, CHEN Qun, ZHAO Jing-sheng. Clinical Application of EPO in Common Malignant Patients Receiving Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2007, 34(06): 451-453. DOI: 10.3971/j.issn.1000-8578.2806 |
| [10] | YIN Tie jun, LIU Qing qing, YANG Jian xia, HU Chang yao. A Study on Dose Level of Carboplatin Combined Chemotherapy in Treatment of Elder Non small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2004, 31(11): 706-708. DOI: 10.3971/j.issn.1000-8578.2073 |
Figures(2) / Tables(3)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: